Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Genomic profiling identifies association of IDH1/IDH2 mutation with longer relapse free and metastasis free survival in high-grade chondrosarcoma.

Zhu G, Nafa K, Agaram N, Zehir A, Benayed R, Sadowska J, Borsu L, Kelly C, Tap WD, Fabbri N, Athanasian E, Boland PJ, Healey JH, Berger MF, Ladanyi M, Hameed M.

Clin Cancer Res. 2019 Oct 15. pii: clincanres.4212.2019. doi: 10.1158/1078-0432.CCR-18-4212. [Epub ahead of print]

PMID:
31615936
2.

Clonally-Related CD5+ CLL/SLL and CD10+ high grade B-cell lymphoma suggests common neoplastic progenitor with branched disease evolution, with therapeutic implications.

Kumar P, Uppal M, Xiao W, Dogan A, Roshal M, Gao Q, Aypar U, Zhang Y, Arcila ME, Moung C, Yao J, Nafa K, Yu W, Syed MH, Park J, Kumar A, Ho C.

Leuk Lymphoma. 2019 Oct 15:1-5. doi: 10.1080/10428194.2019.1675876. [Epub ahead of print] No abstract available.

PMID:
31612754
3.

Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations.

Suehara Y, Alex D, Bowman A, Middha S, Zehir A, Chakravarty D, Wang L, Jour G, Nafa K, Hayashi T, Jungbluth AA, Frosina D, Slotkin E, Shukla N, Meyers P, Healey JH, Hameed M, Ladanyi M.

Clin Cancer Res. 2019 Jun 7. doi: 10.1158/1078-0432.CCR-18-4032. [Epub ahead of print]

PMID:
31175097
4.

The t(11;14)(q13;q32)/CCND1-IGH translocation in chronic lymphocytic leukaemia/small lymphocytic lymphoma: an unusual genetic aberration during the natural clinical course.

Liu Y, Roshal M, Xiao W, Zhang Y, Aypar U, Yu W, Nafa K, Arcila M, Moung C, Dogan A, Park J, Ho C.

Histopathology. 2019 Aug;75(2):291-294. doi: 10.1111/his.13885. No abstract available.

5.

Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions.

Cocco E, Benhamida J, Middha S, Zehir A, Mullaney K, Shia J, Yaeger R, Zhang L, Wong D, Villafania L, Nafa K, Scaltriti M, Drilon A, Saltz L, Schram AM, Stadler ZK, Hyman DM, Benayed R, Ladanyi M, Hechtman JF.

Cancer Res. 2019 Mar 15;79(6):1047-1053. doi: 10.1158/0008-5472.CAN-18-3126. Epub 2019 Jan 14.

PMID:
30643016
6.

Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms.

Arcila ME, Yu W, Syed M, Kim H, Maciag L, Yao J, Ho C, Petrova K, Moung C, Salazar P, Rijo I, Baldi T, Zehir A, Landgren O, Park J, Roshal M, Dogan A, Nafa K.

J Mol Diagn. 2019 Mar;21(2):330-342. doi: 10.1016/j.jmoldx.2018.10.008. Epub 2018 Dec 25.

7.

Next-Generation Sequencing-Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer: Potential Implications for Clinical Management.

Gupta S, Vanderbilt CM, Cotzia P, Arias-Stella JA 3rd, Chang JC, Zehir A, Benayed R, Nafa K, Razavi P, Hyman DM, Baselga J, Berger MF, Ladanyi M, Arcila ME, Ross DS.

J Mol Diagn. 2019 Mar;21(2):307-317. doi: 10.1016/j.jmoldx.2018.10.006. Epub 2018 Dec 18.

8.

Diagnosis of known sarcoma fusions and novel fusion partners by targeted RNA sequencing with identification of a recurrent ACTB-FOSB fusion in pseudomyogenic hemangioendothelioma.

Zhu G, Benayed R, Ho C, Mullaney K, Sukhadia P, Rios K, Berry R, Rubin BP, Nafa K, Wang L, Klimstra DS, Ladanyi M, Hameed MR.

Mod Pathol. 2019 May;32(5):609-620. doi: 10.1038/s41379-018-0175-7. Epub 2018 Nov 21.

9.

Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.

Mandelker D, Zhang L, Kemel Y, Stadler ZK, Joseph V, Zehir A, Pradhan N, Arnold A, Walsh MF, Li Y, Balakrishnan AR, Syed A, Prasad M, Nafa K, Carlo MI, Cadoo KA, Sheehan M, Fleischut MH, Salo-Mullen E, Trottier M, Lipkin SM, Lincoln A, Mukherjee S, Ravichandran V, Cambria R, Galle J, Abida W, Arcila ME, Benayed R, Shah R, Yu K, Bajorin DF, Coleman JA, Leach SD, Lowery MA, Garcia-Aguilar J, Kantoff PW, Sawyers CL, Dickler MN, Saltz L, Motzer RJ, O'Reilly EM, Scher HI, Baselga J, Klimstra DS, Solit DB, Hyman DM, Berger MF, Ladanyi M, Robson ME, Offit K.

JAMA. 2017 Sep 5;318(9):825-835. doi: 10.1001/jama.2017.11137. Erratum in: JAMA. 2018 Dec 11;320(22):2381.

10.

Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, Berger MF.

Nat Med. 2017 Aug 4;23(8):1004. doi: 10.1038/nm0817-1004c. No abstract available.

PMID:
28777785
11.

Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing.

Cheng DT, Prasad M, Chekaluk Y, Benayed R, Sadowska J, Zehir A, Syed A, Wang YE, Somar J, Li Y, Yelskaya Z, Wong D, Robson ME, Offit K, Berger MF, Nafa K, Ladanyi M, Zhang L.

BMC Med Genomics. 2017 May 19;10(1):33. doi: 10.1186/s12920-017-0271-4.

12.

Frequent IDH2 R172 mutations in undifferentiated and poorly-differentiated sinonasal carcinomas.

Dogan S, Chute DJ, Xu B, Ptashkin RN, Chandramohan R, Casanova-Murphy J, Nafa K, Bishop JA, Chiosea SI, Stelow EB, Ganly I, Pfister DG, Katabi N, Ghossein RA, Berger MF.

J Pathol. 2017 Aug;242(4):400-408. doi: 10.1002/path.4915. Epub 2017 Jun 9.

13.

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, Berger MF.

Nat Med. 2017 Jun;23(6):703-713. doi: 10.1038/nm.4333. Epub 2017 May 8. Erratum in: Nat Med. 2017 Aug 4;23 (8):1004.

14.

A case of acute myeloid leukemia with e6a2 BCR-ABL fusion transcript acquired after progressing from chronic myelomonocytic leukemia.

Yao J, Douer D, Wang L, Arcila ME, Nafa K, Chiu A.

Leuk Res Rep. 2017 Jan 31;7:17-19. doi: 10.1016/j.lrr.2017.01.003. eCollection 2017.

15.

Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data.

Middha S, Zhang L, Nafa K, Jayakumaran G, Wong D, Kim HR, Sadowska J, Berger MF, Delair DF, Shia J, Stadler Z, Klimstra DS, Ladanyi M, Zehir A, Hechtman JF.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00084. Epub 2017 Oct 3.

16.

Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status: Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay.

Ross DS, Zehir A, Cheng DT, Benayed R, Nafa K, Hechtman JF, Janjigian YY, Weigelt B, Razavi P, Hyman DM, Baselga J, Berger MF, Ladanyi M, Arcila ME.

J Mol Diagn. 2017 Mar;19(2):244-254. doi: 10.1016/j.jmoldx.2016.09.010. Epub 2016 Dec 25. Erratum in: J Mol Diagn. 2017 May;19(3):485.

17.

Clinical Application of Picodroplet Digital PCR Technology for Rapid Detection of EGFR T790M in Next-Generation Sequencing Libraries and DNA from Limited Tumor Samples.

Borsu L, Intrieri J, Thampi L, Yu H, Riely G, Nafa K, Chandramohan R, Ladanyi M, Arcila ME.

J Mol Diagn. 2016 Nov;18(6):903-911. doi: 10.1016/j.jmoldx.2016.07.004. Epub 2016 Sep 12.

18.
19.

The molecular landscape of extraskeletal osteosarcoma: A clinicopathological and molecular biomarker study.

Jour G, Wang L, Middha S, Zehir A, Chen W, Sadowska J, Healey J, Agaram NP, Choi L, Nafa K, Hameed M.

J Pathol Clin Res. 2015 Oct 29;2(1):9-20. doi: 10.1002/cjp2.29. eCollection 2016 Jan.

20.

Genomic aberrations frequently alter chromatin regulatory genes in chordoma.

Wang L, Zehir A, Nafa K, Zhou N, Berger MF, Casanova J, Sadowska J, Lu C, Allis CD, Gounder M, Chandhanayingyong C, Ladanyi M, Boland PJ, Hameed M.

Genes Chromosomes Cancer. 2016 Jul;55(7):591-600. doi: 10.1002/gcc.22362. Epub 2016 May 9.

21.

Locked Nucleic Acid Probes (LNA) for Enhanced Detection of Low-Level, Clinically Significant Mutations.

Nafa K, Hameed M, Arcila ME.

Methods Mol Biol. 2016;1392:71-82. doi: 10.1007/978-1-4939-3360-0_8.

PMID:
26843048
22.

Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib.

Naidoo J, Sima CS, Rodriguez K, Busby N, Nafa K, Ladanyi M, Riely GJ, Kris MG, Arcila ME, Yu HA.

Cancer. 2015 Sep 15;121(18):3212-3220. doi: 10.1002/cncr.29493. Epub 2015 Jun 10.

23.

Consistent copy number changes and recurrent PRKAR1A mutations distinguish Melanotic Schwannomas from Melanomas: SNP-array and next generation sequencing analysis.

Wang L, Zehir A, Sadowska J, Zhou N, Rosenblum M, Busam K, Agaram N, Travis W, Arcila M, Dogan S, Berger MF, Cheng DT, Ladanyi M, Nafa K, Hameed M.

Genes Chromosomes Cancer. 2015 Aug;54(8):463-471. doi: 10.1002/gcc.22254. Epub 2015 May 29.

24.

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.

Cheng DT, Mitchell TN, Zehir A, Shah RH, Benayed R, Syed A, Chandramohan R, Liu ZY, Won HH, Scott SN, Brannon AR, O'Reilly C, Sadowska J, Casanova J, Yannes A, Hechtman JF, Yao J, Song W, Ross DS, Oultache A, Dogan S, Borsu L, Hameed M, Nafa K, Arcila ME, Ladanyi M, Berger MF.

J Mol Diagn. 2015 May;17(3):251-64. doi: 10.1016/j.jmoldx.2014.12.006. Epub 2015 Mar 20.

25.

Additional Primary Malignancies in Patients with Gastrointestinal Stromal Tumor (GIST): A Clinicopathologic Study of 260 Patients with Molecular Analysis and Review of the Literature.

Hechtman JF, DeMatteo R, Nafa K, Chi P, Arcila ME, Dogan S, Oultache A, Chen W, Hameed M.

Ann Surg Oncol. 2015 Aug;22(8):2633-9. doi: 10.1245/s10434-014-4332-z. Epub 2015 Jan 7. Review.

26.

Novel oncogene and tumor suppressor mutations in KIT and PDGFRA wild type gastrointestinal stromal tumors revealed by next generation sequencing.

Hechtman JF, Zehir A, Mitchell T, Borsu L, Singer S, Tap W, Oultache A, Ladanyi M, Nafa K.

Genes Chromosomes Cancer. 2015 Mar;54(3):177-84. doi: 10.1002/gcc.22230. Epub 2014 Nov 27.

27.

Detection of mutations in myeloid malignancies through paired-sample analysis of microdroplet-PCR deep sequencing data.

Cheng DT, Cheng J, Mitchell TN, Syed A, Zehir A, Mensah NYT, Oultache A, Nafa K, Levine RL, Arcila ME, Berger MF, Hedvat CV.

J Mol Diagn. 2014 Sep;16(5):504-518. doi: 10.1016/j.jmoldx.2014.05.006. Epub 2014 Jul 10.

28.

Induction of sarcomas by mutant IDH2.

Lu C, Venneti S, Akalin A, Fang F, Ward PS, Dematteo RG, Intlekofer AM, Chen C, Ye J, Hameed M, Nafa K, Agaram NP, Cross JR, Khanin R, Mason CE, Healey JH, Lowe SW, Schwartz GK, Melnick A, Thompson CB.

Genes Dev. 2013 Sep 15;27(18):1986-98. doi: 10.1101/gad.226753.113.

29.

Use of touch imprint cytology as a simple method to enrich tumor cells for molecular analysis.

Dogan S, Becker JC, Rekhtman N, Tang LH, Nafa K, Ladanyi M, Klimstra DS.

Cancer Cytopathol. 2013 Jul;121(7):354-60. doi: 10.1002/cncy.21292. Epub 2013 Apr 10.

30.

EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.

Arcila ME, Nafa K, Chaft JE, Rekhtman N, Lau C, Reva BA, Zakowski MF, Kris MG, Ladanyi M.

Mol Cancer Ther. 2013 Feb;12(2):220-9. doi: 10.1158/1535-7163.MCT-12-0620. Epub 2013 Jan 31.

31.

Dedifferentiation in gastrointestinal stromal tumor to an anaplastic KIT-negative phenotype: a diagnostic pitfall: morphologic and molecular characterization of 8 cases occurring either de novo or after imatinib therapy.

Antonescu CR, Romeo S, Zhang L, Nafa K, Hornick JL, Nielsen GP, Mino-Kenudson M, Huang HY, Mosquera JM, Dei Tos PA, Fletcher CD.

Am J Surg Pathol. 2013 Mar;37(3):385-92. doi: 10.1097/PAS.0b013e31826c1761.

32.

Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.

Arcila ME, Chaft JE, Nafa K, Roy-Chowdhuri S, Lau C, Zaidinski M, Paik PK, Zakowski MF, Kris MG, Ladanyi M.

Clin Cancer Res. 2012 Sep 15;18(18):4910-8. doi: 10.1158/1078-0432.CCR-12-0912. Epub 2012 Jul 3.

33.

Melanocytic tumor with GNA11 p.Q209L mutation mimicking a foramen magnum meningioma.

Strom RG, Shvartsbeyn M, Rosenblum MK, Hameed MR, Nafa K, Mikolaenko I, Babu RP.

Clin Neurol Neurosurg. 2012 Oct;114(8):1197-200. doi: 10.1016/j.clineuro.2012.02.030. Epub 2012 Mar 13. No abstract available.

PMID:
22421249
34.

EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.

He M, Capelletti M, Nafa K, Yun CH, Arcila ME, Miller VA, Ginsberg MS, Zhao B, Kris MG, Eck MJ, Jänne PA, Ladanyi M, Oxnard GR.

Clin Cancer Res. 2012 Mar 15;18(6):1790-7. doi: 10.1158/1078-0432.CCR-11-2361. Epub 2011 Dec 21.

35.

BRAF mutation analysis of fine-needle aspiration biopsies of papillary thyroid carcinoma: impact on diagnosis and prognosis.

Colanta A, Lin O, Tafe L, Ghossein R, Nafa K, Mitchell T, Ladanyi M, Arcila M.

Acta Cytol. 2011;55(6):563-9. doi: 10.1159/000333272. Epub 2011 Dec 9.

PMID:
22156467
36.

Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.

Shukla N, Ameur N, Yilmaz I, Nafa K, Lau CY, Marchetti A, Borsu L, Barr FG, Ladanyi M.

Clin Cancer Res. 2012 Feb 1;18(3):748-57. doi: 10.1158/1078-0432.CCR-11-2056. Epub 2011 Dec 5.

37.

High frequency of IDH-1 mutation links glioneuronal tumors with neuropil-like islands to diffuse astrocytomas.

Huse JT, Nafa K, Shukla N, Kastenhuber ER, Lavi E, Hedvat CV, Ladanyi M, Rosenblum MK.

Acta Neuropathol. 2011 Sep;122(3):367-9. doi: 10.1007/s00401-011-0855-6. Epub 2011 Jul 14. No abstract available.

38.

Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay.

Arcila ME, Oxnard GR, Nafa K, Riely GJ, Solomon SB, Zakowski MF, Kris MG, Pao W, Miller VA, Ladanyi M.

Clin Cancer Res. 2011 Mar 1;17(5):1169-80. doi: 10.1158/1078-0432.CCR-10-2277. Epub 2011 Jan 19.

39.

Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping.

Arcila M, Lau C, Nafa K, Ladanyi M.

J Mol Diagn. 2011 Jan;13(1):64-73. doi: 10.1016/j.jmoldx.2010.11.005. Epub 2010 Dec 23.

40.

Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report.

Girard N, Lou E, Azzoli CG, Reddy R, Robson M, Harlan M, Orlow I, Yatabe Y, Nafa K, Ladanyi M, Viale A, Kris MG, Riely G, Miller V, Klein RJ, Matsuo K, Pao W.

Clin Cancer Res. 2010 Jan 15;16(2):755-63. doi: 10.1158/1078-0432.CCR-09-2437. Epub 2010 Jan 12.

41.

CpG methylation analysis--current status of clinical assays and potential applications in molecular diagnostics: a report of the Association for Molecular Pathology.

Sepulveda AR, Jones D, Ogino S, Samowitz W, Gulley ML, Edwards R, Levenson V, Pratt VM, Yang B, Nafa K, Yan L, Vitazka P.

J Mol Diagn. 2009 Jul;11(4):266-78. doi: 10.2353/jmoldx.2009.080125. Epub 2009 Jun 18.

42.

cDNA analysis demonstrates that the BRCA2 intronic variant IVS4-12del5 is a deleterious mutation.

Zhang L, Bacares R, Boyar S, Hudis C, Nafa K, Offit K.

Mutat Res. 2009 Apr 26;663(1-2):84-9. doi: 10.1016/j.mrfmmm.2008.11.010. Epub 2008 Nov 25.

PMID:
19070627
43.

KRAS mutational testing in the selection of patients for EGFR-targeted therapies.

Garcia J, Riely GJ, Nafa K, Ladanyi M.

Semin Diagn Pathol. 2008 Nov;25(4):288-94. Review.

PMID:
19013894
44.

Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.

Riely GJ, Kris MG, Rosenbaum D, Marks J, Li A, Chitale DA, Nafa K, Riedel ER, Hsu M, Pao W, Miller VA, Ladanyi M.

Clin Cancer Res. 2008 Sep 15;14(18):5731-4. doi: 10.1158/1078-0432.CCR-08-0646.

45.

EWSR1-CREB1 is the predominant gene fusion in angiomatoid fibrous histiocytoma.

Antonescu CR, Dal Cin P, Nafa K, Teot LA, Surti U, Fletcher CD, Ladanyi M.

Genes Chromosomes Cancer. 2007 Dec;46(12):1051-60.

PMID:
17724745
46.

Single-amplicon MSH2 A636P mutation testing in Ashkenazi Jewish patients with colorectal cancer: role in presurgical management.

Guillem JG, Glogowski E, Moore HG, Nafa K, Markowitz AJ, Shia J, Offit K, Ellis NA.

Ann Surg. 2007 Apr;245(4):560-5.

47.

Prediction of germline mutations and cancer risk in the Lynch syndrome.

Chen S, Wang W, Lee S, Nafa K, Lee J, Romans K, Watson P, Gruber SB, Euhus D, Kinzler KW, Jass J, Gallinger S, Lindor NM, Casey G, Ellis N, Giardiello FM, Offit K, Parmigiani G; Colon Cancer Family Registry.

JAMA. 2006 Sep 27;296(12):1479-87.

48.
49.

Increased frequency of disease-causing MYH mutations in colon cancer families.

Peterlongo P, Mitra N, Sanchez de Abajo A, de la Hoya M, Bassi C, Bertario L, Radice P, Glogowski E, Nafa K, Caldes T, Offit K, Ellis NA.

Carcinogenesis. 2006 Nov;27(11):2243-9. Epub 2006 Jun 14.

PMID:
16774938
50.

Localization of breast cancer susceptibility loci by genome-wide SNP linkage disequilibrium mapping.

Ellis NA, Kirchhoff T, Mitra N, Ye TZ, Chuai S, Huang H, Nafa K, Norton L, Neuhausen S, Gordon D, Struewing JP, Narod S, Offit K.

Genet Epidemiol. 2006 Jan;30(1):48-61.

PMID:
16206141

Supplemental Content

Support Center